Objective:Over the past two decades there has been a strategic shift in treating laryngeal cancer, with an increasing emphasis on preserving the anatomical structure and function of the larynx, even in cases of intermediate or advanced stages of disease. Open partial horizontal laryngectomies (OPHL) are widely adopted to spare the physiological functions of the larynx while achieving good oncological control. Positive, close or narrow surgical margins remain a critical prognostic factor, with their impact varying by tumour location and laryngeal subsite. This review examines the influence of positive margins on survival and the potential need for adjuvant treatments to optimise functional and oncological outcomes. Methods:This study adhered to PRISMA guidelines. Using the PICOS framework, it included studies on adults with laryngeal squamous cell carcinoma treated by OPHL, focusing on survival and local control outcomes. A systematic search of PubMed, EMBASE, and Cochrane databases from 2000 to 2023 was conducted and eligible studies were selected based on comprehensive inclusion criteria and screening of references. Results:The initial search yielded 675 articles from PubMed, 799 from EMBASE, and 33 from the Cochrane Library. After exclusions and duplicate removal, 57 full-text articles were reviewed, with 8 included for qualitative analysis and 7 for quantitative analysis. A total of 2,715 patients (age range, 16-87 years) were recruited across studies spanning from 2001 to 2021, all of which were retrospective. Among patients, 284 (10%) received neoadjuvant treatment and 627 (23%) underwent adjuvant therapy for positive margins, lymph node involvement and adverse pathological features. Seven studies assessed the association between margin status and recurrence, showing that close/positive margins significantly increased recurrence risk (OR 2.77, 95% CI 1.99-3.87, p < 0.01), with no publication bias detected. Conclusions:This review highlights the challenges in defining and managing resection margins in OPHL for laryngeal cancer. While positive or close margins increase the risk of local recurrence, their effect on overall survival is unclear, emphasising the need for standardised protocols and individualised, multidisciplinary treatment planning.

Background:The present systematic review aims to investigate the survival rates and surgical outcomes of patients with treatment-naïve, intermediate (T3) to early advanced (T4a) laryngeal squamous cell carcinoma (LSCC) managed with open partial horizontal laryngectomies (OPHLs). Methods:A systematic literature search was conducted in PubMed, Embase, and Scopus for studies published between January 2000 and December 2023. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. Inclusion criteria were: patients with histopathological confirmed LSCC; tumor classified as T3 or T4a stage according to the American Joint Committee on Cancer (AJCC) staging system; having undergone OPHL as the primary treatment without any prior therapy; availability of at least one of the following outcomes: overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS), local control (LC), locoregional control (LRC), laryngectomy-free survival (LFS), and laryngo-esophageal dysfunction-free survival (LEDFS). Results:A total of 16 studies were deemed eligible for the qualitative analysis. The cumulative number of patients was 1473. The sample size ranged from 17 to 390 patients. The follow-up period ranged from 0 to 198 months. In patients treated with OPHL for T3, the overall five-year pooled proportions were OS 0.82, DSS 0.88, DFS 0.80, and LFS 0.86, whereas for the T4a case series, they were OS 0.77, DSS 0.89, DFS 0.74, and LFS 0.78. Conclusions:OPHL for selected T3 and low extralaryngeal volume T4a LSCC can guarantee a high rate of oncological success. Accurate patient selection is paramount to differentiate advanced diseases that is amenable to conservative surgery.

Early-stage laryngeal cancer (T1-T2) is commonly treated with organ-preserving techniques such as transoral laser microsurgery (TOLMS) or radiation therapy (RT), both providing comparable oncological outcomes but differing in functional results. Local recurrence occurs in approximately 10% of cases, making salvage surgery a crucial therapeutic option. This multi-institutional study investigates the efficacy of open partial horizontal laryngectomy (OPHL) as a salvage treatment, following recurrent laryngeal squamous-cell carcinoma (LSCC) after failed TOLMS. This analysis includes 66 patients who underwent OPHL between 1995 and 2017, reporting favorable oncological outcomes with overall survival (OS) of 87.4%, disease-specific survival (DSS) of 93.4%, and disease-free survival (DFS) of 85.5%. A recurrence rate of 10.6% was observed post-salvage OPHL, with vascular invasion and advanced pathological staging identified as significant predictors of recurrence. OPHL emerged as an effective organ-preserving alternative to total laryngectomy (TL) in select patients, especially those with limited tumor spread and preserved laryngeal function. The study highlights the importance of careful patient selection and thorough preoperative assessment to improve outcomes, positioning OPHL as a key option in treating recurrent laryngeal cancer and offering oncological control while preserving laryngeal functions.

Supplementary Table and Figure Legends from A DNA Vaccine against ERBB2 Impairs Chemical Carcinogenesis in Random-Bred Hamsters

A large multi-institutional case series of laryngeal cancer (LC) T4a was carried out, including 134 cases treated with open partial horizontal laryngectomies (OPHL) +/- post-operative radiation therapy (PORT). The goal was to understand better whether OPHL can be included among the viable options in selected pT4a LC patients who refuse a standard approach, represented by total laryngectomy (TL) + PORT. All 134 patients underwent OPHL type I (supraglottic), II (supracricoid), or III (supratracheal), according to the European Laryngological Society Classification. Comparing clinical and pathological stages showed pT up-staging in 105 cases (78.4%) and pN up-staging in 19 patients (11.4%). Five-year data on overall survival, disease-specific survival, disease-free survival, freedom from laryngectomy, and laryngo-esophageal dysfunction-free survival (rate of patients surviving without a local recurrence or requiring total laryngectomy and without a feeding tube or a tracheostomy) were, respectively, 82.1%, 89.8%, 75.7%, 89.7%, and 78.3%. Overall, complications were observed in 22 cases (16.4%). Sequelae were observed in 28 patients (20.9%). No patients died during the postoperative period. This large series highlights the good onco-functional results of low-volume pT4a laryngeal tumors, with minimal or absent cartilage destruction, treated with OPHLs. The level of standardization of the indication for OPHL should allow consideration of OPHL as a valid therapeutic option in cases where the patient refuses total laryngectomy or non-surgical protocols with concomitant chemo-radiotherapy.

Background: Glucocorticoids (GCs) represent the mainstay therapy for asthmatics. A subset of severe asthmatics fails to respond to steroid-based therapies, leading to important healthcare costs. Single nucleotide polymorphisms (SNPs) of glucocorticoid receptor genes were associated with a response to GC. We evaluate the possible relation of BclI and A3669G SNPs to clinical, biological and functional characteristics of asthmatics. Methods: We recruited 172 mild-to-severe asthmatic outpatients referring to the Severe Asthma and Rare Lung Disease Unit at San Luigi University Hospital. Clinical data were obtained at recruitment when spirometry tests and peripheral blood sampling were performed. Patients were genotyped for BclI and A3669G through the pyrosequencing assay results. Results: Patients with the A3669G AG genotype were younger, allergic and had higher IgE levels compared to AA genotype (p < 0.05). Moreover, asthmatics with the AA genotype had a lower post-bronchodilator FEV1/FVC ratio than the GG genotype (p < 0.05), and a higher RV/TLC ratio than the AG genotype (p < 0.05). Conclusions: The A3669G AG genotype might be related to type-2 allergic asthma; in particular, allele A of A3669G SNP was associated with GC response in our asthmatics. In conclusion, this observational cross-sectional study suggests a possible role of A3669G SNP as a predictor of asthma severity and phenotype.

Background: High total IgE levels are weak predictors of T2High and have been reported in nonallergic asthma. Therefore, the role of total serum IgE (IgE) in the T2High phenotype is still debated. Objective: This study investigated the reliability of stratifying asthmatics into IgEHigh and IgELow within the T2High and T2Low phenotypes. Methods: This cross-sectional single-center study investigated the association of clinical, functional, and bio-humoral parameters in a large asthmatic population stratified by IgE ≥ 100 kU/L, allergen sensitization, B-EOS ≥ 300/µL, and FENO ≥ 30 ppb. Results: Combining T2 biomarkers and IgE identifies (1) T2Low-IgELow (15.5%); (2) T2Low-IgEHigh (5.1%); (3) T2High-IgELow (33.6%); and T2High-IgEHigh (45.7%). T2Low-IgELow patients have more frequent cardiovascular and metabolic comorbidities, a higher prevalence of emphysema, and higher LAMA use than the two T2High subgroups. Higher exacerbation rates, rhinitis, and anxiety/depression syndrome characterize the T2Low-IgEHigh phenotype vs. the T2Low-IgELow phenotype. Within the T2High, low IgE was associated with female sex, obesity, and anxiety/depression. Conclusions: High IgE in T2Low patients is associated with a peculiar clinical phenotype, similar to T2High in terms of disease severity and nasal comorbidities, while retaining the T2Low features. IgE may represent an additional biomarker for clustering asthma in both T2High and T2Low phenotypes rather than a predictor of T2High asthma “per se”.

Perspective on This Article from A DNA Vaccine against ERBB2 Impairs Chemical Carcinogenesis in Random-Bred Hamsters

Supplementary Figure 2 from A DNA Vaccine against ERBB2 Impairs Chemical Carcinogenesis in Random-Bred Hamsters

Purpose Given the biological differences between females and males, sex-specific evaluations should be carried out to obtain better cancer prevention, diagnosis, and treatment strategies. To this purpose, our aim was to evaluate sex differences for toxicity in a cohort of colorectal cancer (CRC) patients undergoing chemotherapy. Methods We performed a retrospective study in 329 CRC patients. Differences between males and females were tested performing the Mann-Whitney U test or the Fisher exact test. Multivariate logistic regression models were computed to evaluate the association between sex and risk of chemotherapy agent-related toxicity. Results According association sex toxicity, significant differences were observed in the median number of episodes of nausea ( p = 0.044), vomit ( p = 0.007), heartburn ( p = 0.022), thrombocytopenia ( p = 0.005), mucositis ( p = 0.024). Moreover, statistically significant differences between males and females were observed in the distribution of the highest toxicity grades of nausea ( p = 0.024), heartburn ( p = 0.016), and thrombocytopenia ( p = 0.034). Females have an increased risk of vomit ( p = 0.002), alopecia ( p = 0.035), heartburn ( p = 0.005), mucositis ( p = 0.003), and lower risk for thrombocytopenia ( p = 0.005). Conclusion According to the association of sex chemotherapy agent-related toxicities, females resulted on average at a significant increased risk of more common adverse events (constipation, dysgeusia, alopecia, heartburn, vomit, asthenia, nausea, pain events, and mucositis). Sex-tailored CRC chemotherapy treatment is necessary to obtain efficacy avoiding toxicity, based on patients’ biological and genetic characteristics, a vision that would change CRC setting, a stable disease but still orphan of a real tailored approach.

Background: In asthma, exhaled nitric oxide (FENO) is a clinically established biomarker of airway T2 inflammation and an indicator for anti-inflammatory therapy. Objectives: The aim of the study was to identify, in an observational real-world cross-sectional study, the main characteristics of patients with asthma as classified by their FENO level. Method: We stratified 398 patients with stable mild-to-severe asthma according to FENO level as low (≤25 ppb) versus elevated (>25 ppb), subdividing the latter into two subgroups: moderately elevated (26–50 ppb) versus very high FENO (>50 ppb). Clinical, functional, and blood parameters were extrapolated from patients’ chart data and compared with the FENO stratification. Predictors of low and elevated FENO asthma were detected by logistic regression model. Results: Low BMI, higher blood eosinophilia, allergen poly-sensitization, the severest airflow obstruction (FEV1/FVC), and anti-leukotriene use are predictors of elevated FENO values in asthma, as well as persistent rhinitis and chronic rhinosinusitis with or without nasal polyps. Beyond these, younger age, more than 2 asthma exacerbations/year, higher airflow reversibility (post-bronchodilator ∆FEV1), and oral corticosteroid dependence are predictors of very high FENO values. In contrast, obesity, obstructive sleep apnoea syndrome, gastroesophageal reflux disease, arterial hypertension, and myocardial infarction are predictors of low FENO asthma. In our population, FENO correlated with blood eosinophils, airflow obstruction, and reversibility and negatively correlated with age and BMI. Conclusions: Stratifying patients by FENO level can identify specific asthma phenotypes with distinct clinical features and predictors useful in clinical practice to tailor treatment and improve asthmatic patients’ outcomes.

Objective The present study evaluates voice and communication after open partial horizontal laryngectomies (OPHLs), according to surgery and patient-related variables. Methods Fifty-eight patients were included: 18 type I OPHL, 20 type II OPHL and 20 type III OPHL. Acoustic, aerodynamic, endoscopic, perceptual and self-assessment analyses were carried out. Surgery-related variables and patient-related variables were considered for the analysis. Results Type I OPHL revealed the best phonatory outcomes. Type II and type III OPHL showed similar and poor results, with a highly deteriorated voice quality. A significant difference in MTP was found for patients who had both arytenoids/cricoarytenoid units preserved. Age and time from surgery showed significant correlations with voice quality after OPHLs. Conclusions Voice and communication outcomes after OPHLs are heterogeneous and might be influenced by several factors. Knowing variables with a substantial impact on phonatory outcomes may help clinicians in the preoperative decision-making process and the postoperative rehabilitative program.

Pirfenidone and nintedanib are the only two drugs approved for the treatment of idiopathic pulmonary fibrosis (IPF). Both proved to be safe and well-tolerated in clinical trials, but real-world data and direct comparisons are scarce. This real-life study explored the safety profile of pirfenidone and nintedanib with a prolonged follow-up. We retrospectively collected clinical status, adverse events (AEs), and treatment changes from IPF patients who had started an antifibrotic treatment at our centre from December 2011 to December 2020, including 192 patients treated with pirfenidone and 89 with nintedanib. The majority of patients in both groups experienced one or more AEs during the follow-up. A higher proportion of AEs in the nintedanib group were effectively treated with behavioural modifications or additional medications compared with the pirfenidone group (52.5% vs. 40.6%, p = 0.04). Overall, a difference in the impact of AEs due to nintedanib versus pirfenidone resulted in a lower permanent discontinuation of therapy (8.3% vs. 18.3%, p = 0.02), with the latter being associated with a higher risk of drug discontinuation at 48 months after initiation (OR = 2.52, p = 0.03). Our study confirms the safety profile of antifibrotic drugs in IPF but highlights that AEs due to nintedanib are usually easier to manage and lead to fewer cases of permanent discontinuation of therapy.

INTRODUCTION:Asthmatics can experience recurrent exacerbations (AEs), irrespectively of asthma severity. Airway inflammatory monitoring could be fundamental to optimize the asthma management. The present study evaluated whether exhaled NO concentrations in proximal and distal respiratory compartments are different in AE-prone patients in combination with T2 blood biomarkers and resting oxygen saturation (SpO2). METHODS:In this observational cross-sectional study, 91 mild-to-severe asthmatics were enrolled. Clinical characteristics, blood and lung function parameters including SpO2, and FENO were evaluated. On 50 randomly selected patients, CANO and JawNO were also analyzed. Then, patients were stratified in frequent exacerbators (FEs) or non-frequent exacerbators (nFEs), according to AE frequency in the previous year (phase I). Chart data were re-evaluated through a 12-month follow-up period post exhaled NO measurement to detect occurrence of novel AE (phase II). RESULTS:FE asthmatics had poorer asthma control and required higher therapeutic intensity (p < 0.05). FENO, CANO, and JawNO were similar between FE and nFE. FE exhibited higher total serum IgE levels and residual volume values but reduced SpO2 than nFE (p < 0.05); SpO2<96.5% characterized the FE patient (odds ratio = 2.94). In phase II, CANO was higher in the group with novel AE at 1-month post-NO measurement (p < 0.05), but not afterward. A higher prevalence of CANO >6 ppb was detected in asthmatics who developed AE within 1 month, suggesting its potential clinical use as biomarker in predicting near-future AE (RR = 11.20). CONCLUSION:AE-susceptible asthmatics are characterized by air trapping and distal airway inflammation in conjunction with lower oxygen saturation. CANO and SpO2 could exert specific roles, respectively, in predicting AE and monitoring FE asthmatics.

Background: Total serum IgE evaluation is currently not a reliable biomarker for discriminating T2 inflammation. Indeed, IgE concentrations can be altered in other inflammatory states due to tobacco and alcohol exposure, ageing, autoimmunity, parasitic infections, or metabolic syndromes (Biomedicines;9:1684). Aims and objectives: The study aims to analyse the peculiarities of asthmatics with high serum IgE in the absence of other T2 markers. Methods: Demographic, clinical, and functional characteristics of 521 asthmatic subjects were extrapolated from chart data and stratified according to serum total IgE concentrations and T2 inflammation (IgEL: IgE<100IU/mL; IgEH/T2L: IgE≥100IU/mL; IgEH/T2H: IgE≥100IU/mL + T2 inflammation). Results: IgEH/T2L is a rare asthmatic subgroup in the whole population (4.4%) characterised by air trapping (reduced FVC, p<0.05, and increased RV/TLC, p<0.05), greater use of OCS (p<0.05), higher blood neutrophilia (p<0.05), and low FeNO concentrations (p<0.01). IgEH/T2L patients shared features with IgEH/T2H, such as asthma severity (GINA steps), the prevalence of frequent exacerbators and a higher male frequency (approximately 45%). However, IgEH/T2L differ from IgEH/T2H for the older age (p<0.05) and for lower blood eosinophilia (p<0.001). Concerning comorbidities, IgEH/T2L more frequently have GERD (p<0.05), obesity (p<0.01), hypertension (p<0.001), but less rhinitis (p<0.001) than IgEH/T2H. Conclusions: The peculiar inflammation and comorbidity pattern in the group of asthmatics with high serum total IgE and T2 low phenotype further contributes to ruling out serum total IgE from the definition of T2 inflammation. However, it remains a marker of asthma severity, frequent exacerbation, and reduced lung function.

Introduction: Severe asthma is characterised by a wide heterogeneity and complexity. On the basis of clinical and biological markers, different monoclonal antibodies are available for personalised medicine in the setting of severe asthma. Aims and objectives: To characterise retrospectively a severe asthma population stratifying patients on the basis of their eligibility for a biological treatment. Methods: Clinical history, pulmonary function and biological data of 159 severe (GINA STEP 4-5) asthmatic patients were collected. Then, they were stratified in two groups: patients that were eligible for a biologic(wBIO) among Omalizumab, Mepolizumab, Benralizumab or Dupilumab(N=83) and patients that weren’t(sBIO;N=76). Results: wBIO patients were all T2 high(Eos>300/mcl,FeNO>30,history of atopy) with higher FeNO(p<0.05), more peripheral blood Eos(p<0.05), higher total IGE(p<0.05), greater history of atopy (p<0.001), more daily activity limitations(p<0.05), higher exacerbations per year(p<0.05), greater ER accesses for acute asthma(p≤0.05), OCS burts ≥3/year(p<0.05), more adherence to treatment (p<0.05)than sBIO. wBIO group showed higher percentage of rhinitis(p<0.001), sinusitis without nasal polyps(p<0.05), osteoporosis(p<0.05) and ASA intolerance(p<0.05) compared to sBIO. sBIO patients suffered from diabetes(p<0.05), cardiovascular dysfunction(p<0.05), myocardial infarction(p<0.05), bronchiectasis(p<0.05) and had thicker wall airways(p≤0.05) on CT scan compared to wBIO. Conclusions: wBIO had T2 high features and comorbidities as expected, and had more clinical risk criteria (ER access,OCS bursts and daily activity limitation) compared to sBIO while sBIO showed more T2 low associated comorbidities.

Background: Asthma is a heterogeneous condition classifiable into different phenotypes, often characterised by shared and superimposable features (Minerva Med;112:547-563). Recently, it has been shown that plasma fibrinogen concentrations above 361mg/dL can be predictive, in subjects with severe asthma, for the frequent exacerbator phenotype (FE) (JACIp;8:2392-2395.e7). Aims and objectives: The study analyses characteristics of mild-to-severe asthmatics with high plasma fibrinogen (PFH). Methods: Demographic, clinical, and functional characteristics of 335 asthmatic subjects were extrapolated from chart data and stratified according to plasma fibrinogen concentrations (PFH cut-off >361mg/dL). Results: PFH asthmatics are prevalently female (p<0.05), old (p<0.01), and have a longer asthma duration (p<0.05). PFH have a higher BMI (p<0.01) and are frequently classifiable as obese (p<0.01). Functional parameters show that PFH exhibit airflow limitation (reduced FEV1, p<0.001, and FEV1/FVC, p<0.01) and air trapping (lower FVC, p<0.05, and increased RV, p<0.05, and RV/TLC, p<0.0001), resulting in a reduction in SpO2 (p<0.05). PFH are mainly present in the severe asthmatic population (GINA step 5, p<0.0001), frequently FE (p<0.05), for which they receive higher doses of ICS (p<0.01) and make greater LAMA use (p<0.0001). A peculiar feature is the higher incidence of cardiovascular comorbidities (hypertension, p<0.05; heart failure, p<0.05; arrhythmia, p<0.001), which can be correlated to their higher blood neutrophilia (p<0.001). Conclusions: High plasma fibrinogen levels could help identify a severe asthmatic population phenotype with frequent exacerbations associated with increased prevalence of cardiovascular comorbidities.

Introduction: In asthma exhaled nitric oxide (FeNO) is considered a clinical-relevant biomarker for evaluating airway T2 inflammation. FeNO is related to severe and uncontrolled asthma and predicted exacerbations. Aims and objectives: The study aims to describe asthma phenotypes based on FeNO levels. Methods: 320 non-smoking asthmatics were retrospectively stratified according to FeNO values (FeNO-low, ≤25 ppb; FeNO-mid, 26-50 ppb; FeNO-high, >50 ppb). Clinical, functional and blood parameters in stable mild-to-severe asthmatics were extrapolated from the chart data. Results: FeNO-high showed higher prevalence in rhinitis (p <0.01 vs FeNO-low) and nasal polyposis (p <0.05 vs FeNO-mid, and p <0.01 vs FeNO-low), however they had a lower prevalence of GERD and arthropathy (p <0.05) than FeNO-low. The FeNO-high exhibited a greater airflow obstruction (TI%, p <0.05 vs FeNO-low), although displaying a better reversibility (∆FVC, p <0.05, and ∆FEV1, p <0.01) than FeNO-mid and FeNO-low. FeNO-high revealed a worsening in daily activity limitations (p <0.05 vs FeNO-mid). Concerning blood biomarkers, FeNO-high showed higher blood eosinophilia (p <0.001) and a higher percentage of patients with blood eosinophils >300cells/µL (p <0.001 vs FeNO-low and p <0.05 vs FeNO-mid). Finally, FeNO-high displayed a higher prevalence of highly-frequent exacerbators (≥3 asthma exacerbations per year, p <0.01, OR=3.2). Conclusions: The main features of FeNO-high asthma phenotype are elevated blood eosinophilia, greater reversible airflow obstruction and higher risk of frequent exacerbations associated with upper airways comorbidities. FeNO monitoring is a non-invasive test useful for patients who may also benefit from personalized therapeutic strategies.

INTRODUCTION: Asthma is a complex disorder characterized by expiratory airflow limitation, wheeze, shortness of breath, chest tightness and cough, which can vary over time and in intensity. Being highly heterogeneous, asthma was characterized and classified in several asthma phenotypes and endotypes from 1947 until today. The present systematic review aims to summarize and describe evidence that was published in the last ten years in the field of asthma phenotyping and endotyping. EVIDENCE ACQUISITION: The systematic review resumed high-quality evidence (clinical trials and randomized control trials) retrieved on MEDLINE and EMBASE databanks and involving adult asthmatic populations. Analyses of literature were conducted according to PRISMA and CASP guidelines. EVIDENCE SYNTHESIS: Querying MEDLINE and EMBASE databanks, 5019 and 12261 entries were retrieved, respectively. Applying limitations for year of publication, age of participants, and type of publication, the search results were reduced to 98 and 132 articles, respectively. After data abstraction and resolution of duplications, only 50 articles were further evaluated. The research products were then classified first in macro-areas of interest (phenotypes or endotypes) and then in detailed micro-areas. CONCLUSIONS: This systematic review overviews the principal findings available from high-quality literature in the last decade concerning asthma phenotypes and endotypes. Asthma has been described from different points of view, characterizing symptoms, microbiota composition, comorbidities, viral infections, and airway and/or systemic inflammatory status. The comprehension of precise mechanisms underlying asthma pathogenesis is thereby the basis for the development of novel therapeutic strategies, likely essential to the development of precision medicine.

Asthma is a heterogeneous and complex condition characterized by chronic airway inflammation, which may be clinically stratified into three main phenotypes: type 2 (T2) low, T2-high allergic, and T2-high non-allergic asthma. This real-world study investigated whether phenotyping patients with asthma using non-invasive parameters could be feasible to characterize the T2-low and T2-high asthma phenotypes in clinical practice. This cross-sectional observational study involved asthmatic outpatients (n = 503) referring to the Severe Asthma Centre of the San Luigi Gonzaga University Hospital. Participants were stratified according to the patterns of T2 inflammation and atopic sensitization. Among outpatients, 98 (19.5%) patients had T2-low asthma, 127 (25.2%) T2-high non-allergic, and 278 (55.3%) had T2-high allergic phenotype. In comparison to T2-low, allergic patients were younger (OR 0.945, p < 0.001) and thinner (OR 0.913, p < 0.001), had lower smoke exposure (OR 0.975, p < 0.001) and RV/TLC% (OR 0.950, p < 0.001), higher prevalence of asthma severity grade 5 (OR 2.236, p < 0.05), more frequent rhinitis (OR 3.491, p < 0.001) and chronic rhinosinusitis with (OR 2.650, p < 0.001) or without (OR 1.919, p < 0.05) nasal polyps, but less common arterial hypertension (OR 0.331, p < 0.001). T2-high non-allergic patients had intermediate characteristics. Non-invasive phenotyping of asthmatic patients is possible in clinical practice. Identifying characteristics in the three main asthma phenotypes could pave the way for further investigations on useful biomarkers for precision medicine.